Loading
Surgeon-scientist whose personalised mRNA vaccine trial showed pancreatic cancer can provoke lasting T-cell immunity.
Vinod Balachandran led the phase 1 trial of the individualised mRNA neoantigen vaccine autogene cevumeran after pancreatic cancer surgery, showing that half of patients mounted durable neoantigen-specific T cells and that responders had markedly longer recurrence-free survival. His earlier Nature paper showed long-term pancreatic cancer survivors have high-quality neoantigens. He leads the phase 2 IMCODE003 trial.
The strongest human evidence that a cancer vaccine can make durable T cells in a tumour with few mutations; the randomised phase 2 IMCODE003 (260 patients, primary completion listed for January 2031) is the test of whether that translates into fewer relapses.
Pancreatic cancer was thought to be immunologically inert because of its low mutation burden; this study showed that with the right vaccine platform its few neoantigens can still be targeted. It is the strongest human evidence so far that personalised cancer vaccines can generate durable, tumour-specific immunity, and it justifies the randomised trials now running in pancreatic cancer and melanoma. Benefit is not yet proven, because responders may simply have had more immunogenic tumours.
It defines who a homologous recombination result should send to platinum: core-gene and biallelic carriers, germline or somatic, rather than any repair-gene variant.
It is the proof that T cells can control pancreatic cancer in some people, and the scientific basis for the personalised neoantigen vaccines now in trials.
Shares RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines and the tags vaccine, immunotherapy.
Shares Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering), RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines.
Shares Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer, Autogene cevumeran, Personalised neoantigen (mRNA) vaccines, Pancreatic ductal adenocarcinoma.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pancreatic.